Discover key facts about the healthcare market in France and learn about our latest market research for our pharmaceutical, medical device, and healthcare sector clients.
Key facts about the French health market:
Funding in the French healthcare system
In France there is mandatory enrolment in a statutory health insurance system. This covers most costs for hospital, physician, and long-term care, as well as prescription drugs.
Patients are responsible for co-insurance and co-payments, balancing bills for physician charges that exceed covered fees.
Health technology assessment in the France
The French domestic market for pharmaceuticals is highly regulated, with continued pressure from the French public health authorities to lower sales costs of drugs and medicines for end consumers.
The Haute Autorité de Santé (HAS) are responsible for the evaluation of pharmaceuticals and medical devices, and define both SMR and ASMR scores, which impact on pricing and reimbursement decision . However, medical devices have a range of reimbursement processes available, including a fast-track reimbursement process introduced in June 2023.
French payers’ primary focus:
The French market is clinically focused.
To discuss your launch strategy for France with our experts, or to enquire about market research services, get in touch using the form below.
Our work in the French market
At Mtech Access, we have a global network of Associates, including experts across France. Their insights inform our primary research and validate our secondary research.
Here are just a few examples of how we have supported clients looking to understand and influence the healthcare market in France:
View Case StudyExploring funding and reimbursement routes for digital health technologies across EU4, UK and US
View Case StudyResearching market access pathways, reimbursement requirements and implications of orphan drug designation for a rare disease product
View Case StudyModelling pricing and market dynamics in a competitive therapeutic landscape across the EU4 and UK markets
View Case StudyGaining global payer insights to inform clinical trial design, price and market access strategy
View Case StudyReviewing HTA decisions in key markets across the globe
View Case StudyChallenging European policy proposals with an evidence-driven submission on behalf of a cross-industry consortium
More French market insights and research
EU Joint Clinical Assessment (JCA) – implications for Pharma and Medtech
Our health technology assessment experts provide an overview of the EU Joint Clinical Assessment (JCA) and what it means for Pharma and Medical Device manufacturers launching new technologies from 2025
Market access and reimbursement in key European markets
In this introductory guide, our Global market access experts present an overview of the reimbursement landscape in key European healthcare systems, including Germany.
